CME for Physicians
CNE for Nurses
CPE for Pharmacists
CANCER EDUCATION FOR PHYSICIANS, NURSES, AND PHARMACISTS - Taught by the Experts

Chair

Paul A. Bunn MD
Paul A. Bunn, Jr., MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO
Disclosures
Consulting Fees (e.g., advisory boards): AstraZeneca, BMS, Genentech, Lilly, Merck, Merck Serono, Takeda

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 

Faculty

Joshua  Bauml MD
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures
Grant Research Support: Merck, Clovis, Carevive Systems, Novartis, Bayer;
Consultant: Clovis, BMS, AstraZeneca, Celgene, Boehringer Ingelheim, Merck, Guardant Health, Genentech
 
Marianne  Davies DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Clinical Instructor in Nursing
Thoracic Oncology Program
Yale Comprehensive Cancer Center
Yale Schools of Nursing and Medicine
New Haven, CT
Disclosures
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): Merck, BMS, Genentech, AstraZeneca
 
Edward B. Garon MD
Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures
Contracted Research: AstraZeneca, BMS, Genentech, Eli Lilly, Merck, Novartis, Iovance, Mirati, Dynavax

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Richard  Gralla MD, FACP
Richard Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
Disclosures
Consulting Fees (e.g., advisory boards): Merck, Helsinn
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): Merck, Helsinn, Purdue
Contracted Research: Merck

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Jim  Koeller MS
Jim Koeller, MS
Professor,
University of Texas at Austin
College of Pharmacy,
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine, Pharmacotherapy Education & Research
University of Texas Health Science Center at San Antonio
San Antonio, TX
Disclosures
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): Lilly
 
Ronald B. Natale MD
Ronald B. Natale, MD
Director of the Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosures
Contracted Research: Merck, Tesaro, AstraZeneca, BMS
Other: Spouse is an AstraZeneca employee
 
Joel  Neal MD, PhD
Joel Neal, MD, PhD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA
Disclosures
Consulting Fees: Clovis, CARET/Physicians Resource Mgmt, Nektar, BI, ARMO Biosciences, ARIAD
Contracted Research: Genentech/Roche, Merck, Arqule, Novartis, Exelixis, BI, Nektar

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Suresh S. Ramalingam MD
Suresh S. Ramalingam, MD
Professor, Department of Hematology and Medical Oncology
Roberto C. Goizueta Distinguished Chair for Cancer Research
Director, Division of Medical Oncology
Department of Hematology and Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Director, Lung Cancer Program
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute of Emory University
Atlanta, GA
Disclosures
Grant Research Support: Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Lilly, Genentech, Merck, AstraZeneca, Takeda, Loxo Oncology;
Consultant: Nektar, Novartis, Pfizer.
 
Greg  Riely MD
Greg Riely, MD
Medical Oncologist
Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
Disclosures
Contracted Research: Pfizer, Novartis, Roche, Takeda (funding to institution)

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Jared  Weiss MD
Jared Weiss, MD
Assistant Professor of Medicine
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Disclosures
Consulting: AstraZeneca, Biodesix, Clovis Oncology, Eli Lilly, EMD Serono, and OncoPlex
Research: AstraZeneca, Celgene, Merck, Novartis, and Pfizer
 
Deborah  Wong MD, PhD
Deborah Wong, MD, PhD
Professor, Oncology
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA
Oncology Nursing Faculty
Disclosures
Consulting Fees: Bristol-Myers Squibb
 
“Personalized Therapies & Best Clinical Practices for Lung Cancer and Head & Neck Cancer--Update 2019” CASE-BASED LEARNING  a 20-Webinar Course Curriculum
“Personalized Therapies & Best Clinical Practices for Lung Cancer and Head & Neck Cancer--Update 2019” CASE-BASED LEARNING a 20-Webinar Course Curriculum
Start Date: 11/14/2019
Date Expires: 11/14/2020

Agenda

SMALL CELL LUNG CANCER: New & Emerging Strategies Replacing the 30-Year-Old Standard of Care
Webinar #3101: Therapeutic Strategies for ES- Small Cell Lung Cancer (SCLC): Systemic & Maintenance Therapy for Treatment-Naïve ES-SCLC Patients, and CNS Therapy (local & systemic)
Paul A. Bunn, Jr., MD
Webinar #3102: Molecular Biomarkers: Developing Precision Medicine Strategies for SCLC
Joshua Bauml, MD
Webinar #3103: Salvage Therapy for ES-Small Cell Lung Cancer: Checkpoint Inhibition plus Chemotherapy; PARP Inhibitors & Other Novel Targeted Therapy Strategies
Suresh S. Ramalingam, MD
Strategies for EARLY-STAGE NSCLC and OLIGOMETASTATIC NSCLC
Webinar #3104: Early-Stage NSCLC
Jared Weiss, MD
Webinar #3105: Oligometastatic NSCLC
Joshua Bauml, MD
Strategies for NON-SQUAMOUS NSCLC and SQUAMOUS NSCLC
Webinar #3106: Should a medical oncologist delay therapy for a treatment-naïve NSCLC patient while waiting for molecular testing results to determine if a driver mutation exists?
Paul A. Bunn, Jr., MD
Webinar #3107: Total Mutation Burden as a clinical tool for managing NSCLC patients today.
Edward B. Garon, MD
Webinar #3108: What are the options for initial therapy of NON-SQUAMOUS NSCLC? Which patients are candidates for the various options?
Suresh S. Ramalingam, MD
Webinar #3109: What are the options for initial therapy SQUAMOUS NSCLC? Which patients are candidates for the various options?
Jared Weiss, MD
Special Topics for Nurses, Pharmacists and Physicians
Webinar #3110: Physician Reimbursement Update (e.g., MACRA, etc.) (primarily for pharmacists & physicians)
Jim Koeller, MS
Webinar #3111: Integrating QI into Community Oncology Practices for Lung Cancer (primarily for physicians)
Richard Gralla, MD, FACP
Webinar #3112: Managing Immune Therapy irAEs (primarily for nurses and Nurse Practitioners)
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
The New Therapeutic Landscapes for ALK-ROS-1 REARRANGEMENT & EGFR-POSITIVE NSCLC
Webinar #3113: Should the most effective anti-EGFR- or anti-ALK/ROS1-directed therapy be used up front or should it be saved for after Acquired Resistance (AR)?
Greg Riely, MD
Webinar #3114: ALK-Positive-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-gen. agents)
Paul A. Bunn, Jr., MD
Webinar #3115: EGFR-Positive-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd and 3rd-gen. agents)
Greg Riely, MD
Webinar #3116: What are the “SALVAGE” NSCLC Therapy Standards of Care? How can they be optimally sequenced?
Ronald B. Natale, MD
New & Emerging NSCLC Driver Mutations “BEYOND” EGFR & ALK/ROS1: Optimal Therapies & Testing
Webinar #3117: Treatment Options for New & Emerging NSCLC Mutations: Maximizing Targeted Therapy Outcomes
Joel Neal, MD, PhD
Webinar #3118: Are plasma-based NGS testing and tissue-based NGS testing interchangeable?
Edward B. Garon, MD
Webinar #3119: Molecular Testing for NSCLC Patients: Where are we today? What’s coming?
Edward B. Garon, MD
Webinar #3120: Squamous Cell Cancer of the Head & Neck (SCCHN): New Advances with Checkpoint Inhibition-Based Strategies
Deborah Wong, MD, PhD

Overview

The overall objective of the 20 archived Webinars for one year is to address the large number of professional and clinical Quality Performance Practice Gaps resulting from the continual integration of novel immune therapies, novel targeted therapies and chemotherapies into the numerous current, emerging and evolving monotherapy and combination therapy standards of care, for treating thoracic malignancies (SCLC, NSCLC, Head & Neck Cancer) as generated by the FDA approvals, and the NCCN, ASCO and other guidelines.

The emphasis of the 20 Webinars is on immune therapies, targeted therapies and molecular testing that are causing the greatest changes in standards of care for NSCLC, SCLC and Head & Neck Cancer, and as reported to us by the oncologists, pathologists, nurses, pharmacists and other HCPs that we interviewed are the basis of the most important professional Quality Performance Practice Gaps that learners want addressed with these 20 archived Webinars. Clearly, the exciting future for treating lung cancer and head & neck cancer has arrived and is “hear-now” with new clinical data on combinations and sequences of immune therapy and targeted therapy and chemotherapy to improve patient outcomes.


Educational Need

In 2018, an estimated 234,030 adults (121,680 men and 112,350 women) in the United States will be diagnosed with lung cancer—a total of both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). And in 2018, an estimated 150,040 people will die from all lung cancers. SCLC: Approximately 30,000 people will be diagnosed with SCLC in 2018. Approximately 70% of the SCLC patients present with stage IV disease, where the treatment approach is only palliative. The SCLC prognosis is the poorest among all types of lung cancer, with an overall and dismal survival rate at 5 years of between 2 and 5%.

NSCLC represents about approximately 85 to 90% of all lung cancers. Survival rates for NSCLC patients vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancers are diagnosed at late stages of disease, especially Stages 2 and mostly 3, the five-year survival rate for Stage 4 NSCLC is approximately two percent.

Head & Neck Cancer accounts for about 4% of all cancers in the United States. This year, an estimated 64,690 people (47,650 men and 17,040 women) will develop head and neck cancer. While younger people can develop the disease, most people are older than 50 when they are diagnosed.


Target Audience

The target audience includes both academic/hospital-based, and, also community-based/private practice oncologists, pathologists, immunologists, diagnostic radiation clinicians, radiation oncologists, surgical oncologists, fellows, cancer pharmacists, cancer nurses, Advanced Nurse Practitioners in Oncology, Oncology Physician Assistants and other allied HealthCare Practitioners (HCPs) who treat and care for all NSCLC, SCLC, and Head & Neck Cancer patients. Although some of the focus is on community-based practices, because of the very rapid pace at which all data is changing, all clinicians in all practice settings, including academia, are targeted, including research-based oncologists and all allied HCPs involved in thoracic oncology. All of these clinicians will benefit from the 20 Internet-based, archived Webinars.

Learning Objectives

Physician
  1. Understand how to select from among all options to provide the optimal salvage therapy for patients with ES-Small Cell Lung Cancer after initial therapy with the 2019 FDA-approved atezolizumab regimen using bevacizumab and chemotherapy.
  2. Understand how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  3. Compare and Contrast Molecular Testing Methodologies for Non-Small Cell Lung Cancer.
  4. Evaluate when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
  5. Compare and contrast the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
  6. Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  7. Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  8. Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  9. Compare and contrast the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  10. Compare and contrast the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  11. Understand how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  12. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous and squamous Non-Small Cell Lung Cancer.
  13. Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease and the two FDA approved checkpoint inhibitors for Stage 3 NSCLC, durvalumab and pembrolizumab.
  14. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  15. Compare and contrast the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
  16. Evaluate the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.
Nurse
  1. Understand how to select from among all options to provide the optimal salvage therapy for patients with ES-Small Cell Lung Cancer after initial therapy with the 2019 FDA-approved atezolizumab regimen using bevacizumab and chemotherapy.
  2. Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  3. Describe Molecular Testing Methodologies for Small Cell Lung Cancer.
  4. Review the NGS testing methodologies for patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
  5. Define the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
  6. Identify the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  7. Recall the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  8. Review the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  9. List the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  10. Review the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  11. Describe how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  12. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  13. Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease and the two FDA approved checkpoint inhibitors for Stage 3 NSCLC, durvalumab and pembrolizumab.
  14. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  15. Review the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
  16. Describe the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.
Pharmacist
  1. Understand how to select from among all options to provide the optimal salvage therapy for patients with ES-Small Cell Lung Cancer after initial therapy with the 2019 FDA-approved atezolizumab regimen using bevacizumab and chemotherapy.
  2. Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  3. Describe Molecular Testing Methodologies for Small Cell Lung Cancer.
  4. Review the NGS testing methodologies for patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
  5. Define the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
  6. Identify the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  7. Recall the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  8. Review the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  9. List the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  10. Review the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  11. Describe how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  12. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  13. Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease and the two FDA approved checkpoint inhibitors for Stage 3 NSCLC, durvalumab and pembrolizumab.
  14. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  15. Review the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
  16. Describe the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.

CME/CE Accreditation and Credit Designation

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this enduring activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 10 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-19-001-H01-P
Credits: 10 hours (1 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 10 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

 

Educational Support

Sincere appreciation is extended to companies providing support for this independent educational activity.

Bristol-Myers Squibb
Takeda Oncology
Loxo Oncology
Celgene